Skip to content
Screener

Reported November 12, 2026 · Before market open

Revenue-Miss by $755.6K
EPS-$0.10Beat by $0.03
Revenue estimate$755.6K
EPS estimate-$0.13
“During the third quarter, we continued to make strong progress across our clinical, manufacturing and commercial readiness activities as we advance toward a potential BLA submission for TSHA-102. With all patients dosed and having cleared the acute post-dosing safety monitoring period in our REVEAL pivotal and ASPIRE trials with no severe treatment-related serious adverse events or dose-limiting toxicities observed across all studies, our focus now turns to delivering a robust dataset to support our planned BLA submission and further establish the potential of TSHA-102 to address the significant unmet need in Rett syndrome. In parallel, we achieved an important manufacturing milestone with the successful completion of our BLA-enabling PPQ manufacturing campaign, which met the predefined acceptance and comparability criteria previously reviewed with FDA. Importantly, the results further demonstrated our ability to consistently manufacture high-quality product at commercial scale, including an encouraging single-digit empty capsid percentage, a key indicator of product quality that contributes to patient safety. Looking ahead, we believe the first half of 2027 could be a transformative period for Taysha with our plan to report data from the six-month interim analysis of our REVEAL pivotal trial along with expected FDA feedback on our BLA submission pathway, and the anticipated nomination of a second gene therapy development program with a high unmet medical need and robust commercial opportunity as we begin building a broader CNS genetic medicine franchise.”
Sean P. Nolan

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue-—
Operating income-$41.9M-23.1%
Net income-$39.1M-19.5%
EPS (diluted)-$0.10-11.1%

Balance sheet

See full
Cash & equivalents$422.8M+42.2%
Total debt$54.6M-21.0%
Total equity$357.0M+63.0%
Total assets$435.0M+37.4%

Cash flow

See full
Operating cash flow-$32.9M-36.2%
CapEx$443.0K+310%
Free cash flow-$33.4M-37.4%

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$1.42B+33.6%
Enterprise value$1.06B+26.1%
P/S259.6×+90.7×

Profitability

See full
Operating margin-2,935.4%+12,813pp
Net margin-2,844.6%+11,116pp
FCF margin-2,582.6%+27,290pp

Returns & leverage

See full
Return on equity-54.2%-7.7pp
Debt / equity0.2×-0.2×
Current ratio18.6×+8.1×

FAQ

When did Taysha Gene Therapies, Inc. report Q3 2026 earnings?
Taysha Gene Therapies, Inc. (TSHA) reported Q3 2026 earnings on November 12, 2026 before market open.
What were Taysha Gene Therapies, Inc.'s Q3 2026 revenue and EPS?
Taysha Gene Therapies, Inc. reported revenue of - and eps of $-0.10 for Q3 2026.
Did Taysha Gene Therapies, Inc. beat estimates in Q3 2026?
Revenue missed the consensus estimate of $755.6K by $755.6K. EPS beat the consensus estimate of $-0.13 by $0.03.
How did Taysha Gene Therapies, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 11.1% from $-0.09.
Where can I find Taysha Gene Therapies, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-456974) and the 10-Q periodic report (0001193125-26-456949) directly on SEC EDGAR. The filing index links above go to sec.gov.